Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss
Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders.
Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders.
Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.'
Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress.
Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management:
Three small molecule agonist programs (GIP, Apelin, Amylin)
One small molecule antagonist program (GIP)
Two long-acting programs (targets undisclosed)
Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally.
Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs:
Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss.
Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously.
Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations.
Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies.
Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains.
Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration.
Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025.
–END–
About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.
Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation.
Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
Enquiries:
Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life
MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com
Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
O2, Three and iD Mobile most complained-about mobile providers
TalkTalk attracted the most complaints from broadband consumers and O2, Three and iD Mobile were the most complained-about mobile providers over the last quarter, latest Ofcom figures show. Plusnet generated the fewest complaints among broadband providers, while EE, Sky Mobile, Tesco Mobile and Vodafone were the least complained-about mobile providers, the regulator said. Ofcom publishes figures for complaints it receives about the UK's main landline, mobile broadband and pay-TV providers every quarter. It said O2's broadband customers mainly complained about how their grievances were handled, while Three customers were most often concerned about billing, pricing and charges. EE and TalkTalk were the most complained-about landline providers, while Utility Warehouse generated the fewest complaints. Virgin Media was the pay-TV provider that generated the most complaints, while Sky and TalkTalk customers were the happiest with their service. The figures cover complaints received by Ofcom from January to March. They remained similar to the previous quarter, but complaints about fixed broadband and pay-TV increased, the regulator said. Ofcom said it compiled and published the figures to help consumers see how their providers performed in relation to others, and to help them choose a new provider if they were thinking of switching. An Ofcom spokeswoman said: 'It's positive to see stable complaints numbers overall, which have come down over time. 'But this doesn't mean telecoms companies can sit back when it comes to customer service. Some providers have seen complaints about them increase, so we want to see further improvements.'
Yahoo
5 minutes ago
- Yahoo
DC Singh's blueprint for turning Scottish Cashmere into a multi-sector powerhouse
In the global business arena, few stories are as compelling as that of Didar 'DC' Singh Chalana. DC Singh's track record shows that he's not only creative, but he's also a mastermind who can turn virtually any business into profit. A man who built a global brand from scratch in luxury cashmere, expanded into property and healthy food, and now leads the charge in technology, all underpinned by a rare blend of design flair and entrepreneurial strategy. DC Singh: From Retail Assistant to Luxury Empire Builder In 2008, with no formal business training and finite resources, a young DC Singh landed in Edinburgh working as a retail sales assistant. He observed a crowded cashmere tourism market, yet the quality was lacking. At that moment, the seed of Edinburgh Cashmere was planted: a premium, design-led brand offering 100% pure cashmere and lambswool with unmatched craftsmanship. By 2014, Singh had officially launched Edinburgh Cashmere, and over the next decade he produced over 500 unique designs, from iconic 'DC Classic Check' tartan patterns to bespoke monograms. DC Singh Collaborates with Hollywood & Bollywood Stars and Strategic Business Partners for a Global Expansion What truly catapulted the brand to global relevance was Singh's knack for collaboration. He partnered with luxury fashion houses across Italy, France, and the UK, building exclusive lines, manufacturing limited editions, and co-creating special merchandise for football clubs. His factories became trusted suppliers to the world's top fashion names. These collaborations not only showcased his design excellence but also proved wildly profitable, often generating multi‑million-pound revenues per collection. Observers often refer to his influence in fashion and business as a kind of 'magic touch'. Flagship Brand & Global Expansion Singh rapidly scaled Edinburgh Cashmere internationally, opening flagship stores and launching e‑commerce deliveries in markets including the UK, USA, France, Japan, UAE, and beyond. In Dubai alone, the brand will soon debut a major store presence. International fashion media took note. The brand's collections have been featured in Vogue, Tatler, GQ, Grazia, and Singh's products frequently appear at Milan and Paris Fashion Weeks solidifying his design credentials and global cachet. Design‑Driven, Profit‑Focused: The Strategy That Works Singh's entrepreneurial philosophy combines uncompromising quality, trendsetting design, and strategic partnerships. He designed every logo and pattern personally and oversaw every production stage from raw material source to finishing. That design discipline, coupled with strong business tactics, enabled consistent million‑pound profits across verticals. His ability to anticipate market trends whether launching tartans or monograms or pivoting to health food and tech is a defining feature of his success. Singh's business mindset consistently focused on long-term value, not short-term gain. Diversification: Jewellery, Food, Real Estate & Health Beyond fashion, Singh built a multifaceted portfolio: Luxury Jewellery: His Lucchi line fuses Indian craftsmanship with Western design for couture jewellery and accessories. Healthy Food Franchise: With chefs and nutritionists, Singh created DC Tasty a fast-food concept offering healthy burgers and pizzas that is now poised for global franchise roll-out. Real Estate Development: His property arm spans residential and commercial projects in the UK and beyond, often employing eco-conscious construction and affordable housing methods. Each venture links back into his brand ethos premium, sustainable, and design focused. Technology: A New Frontier Perhaps the most disruptive next phase: Singh's expanding tech initiatives. He recently launched a ride‑hailing app promising higher earnings for drivers and savings for riders, with integrated environmental and safety standards. Beyond that, he plans to develop a suite of apps logistics, food delivery, AI-driven recommendation engines, and virtual showroom tools for both in-house brands and partner ecosystems. These platforms are being built with Silicon Valley partners, signalling significant scalability. Collaboration Grand Slam: Jacob & Co., Manish Malhotra & Expanding into Caribbean Sportswear Partnerships Singh's flair for partnerships took a bold leap recently with new collaborations: A limited-edition luxury watch line with Jacob & Co. A luxury lifestyle and couture collection with Bollywood legend Manish Malhotra High-performance sportswear for Caribbean football clubs, blending aesthetics and function. These ventures extend subjects from high fashion to sports and entertainment all underpinned by Singh's design magic and strategic planning. Sustainability and Ethics: Core Business, Not Side Note Sustainability isn't optional in Singh's ventures, it's foundational. From environmentally friendly dyeing techniques and energy-efficient manufacturing to ethical sourcing, each operation reflects a high-standard approach to environmental and social responsibility. He ensures fair labour conditions, local supplier partnerships, and minimal waste demonstrated that luxury and ethics can coexist profitably. The Magical Profits: Design + Business Intelligence Critics and industry insiders often invoke 'DC's magic touch' the rare ability to turn design vision into sustainable profit. Whether launching a tartan scarf line or co‑designing couture with Malhotra, Singh's projects routinely generate multi‑million dollar returns. Where most entrepreneurs split time between design and operations, Singh does both seamlessly creating products that resonate emotionally and deliver investor returns. Global Reach: Celebrities, Runways, and Retail Singh's brands feature in global fashion weeks, celebrity wardrobes, and elite publications. His collections appear at Milan, Paris, and New York; his scarves and sweatshirts have been seen on Hollywood stars and sporting figures. He uses such platforms strategically not just for exposure but for sustained credibility and traction in luxury markets. 2025 and Beyond: What's Next? Tech Rollout: Scaling ride‑hailing, food‑delivery, and logistics apps across major cities. Fashion Collaborations: New capsule collections with elite partners, sport clubs, and cultural fashion houses. Lucchi Jewellery Launch: Expanding globally into lifestyle and home décor. Global Franchises: DC Tasty to open in UAE, UK, and potentially US markets. Real Estate Expansion: Launching sustainable housing and commercial developments. Conclusion: A Formula for Modern Entrepreneurial Legacy DC Singh illustrates what's possible when design, strategy, ethics, and ambition intersect. From a small cashmere label in Edinburgh to a global empire spanning fashion, real estate, healthy food, and tech his journey reflects consistent excellence and calculated vision. His ever-growing valuations and dynamic collaborations underscore a core principle: quality first, design-led innovation always, profit by design. In 2025 and beyond, DC Singh isn't just broader and richer his story is now shaping global entrepreneurial standards. He isn't just a businessman. He's a designer-CEO, a strategic partner, a tech innovator, and above all, a visionary building an enduring brand all from scratch. DC Singh's Official Website Edinburgh Cashmere Official Online Store DC Milan Follow the socials to learn the latest about these luxury creations: Edinburgh Cashmere Instagram Facebook Twitter Google LinkedIn Pinterest YouTube
Yahoo
5 minutes ago
- Yahoo
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved the primary and all key secondary endpoints, including demonstrating improvements in a number of cardiovascular risk factors With these results, Lilly is on track to submit orforglipron to global regulatory agencies by year-end and is making substantial investments to meet anticipated demand at launch INDIANAPOLIS, Aug. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults with obesity, or overweight with a weight-related medical problem and without diabetes. At 72 weeks, all three doses of orforglipron, met the primary endpoint and all key secondary endpoints compared to placebo, delivering clinically meaningful weight loss as an adjunct to a healthy diet and physical activity. For the primary endpoint, orforglipron 36 mg, taken once per day without food and water restrictions, lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo using the efficacy estimand.1 "Obesity is one of the most pressing global health challenges of our time, driving global chronic disease burden and impacting more than one billion people worldwide," said Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health. "With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments. With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." In the ATTAIN-1 trial, orforglipron met the primary endpoint of superior body weight reduction compared to placebo. Participants taking the highest dose of orforglipron lost an average of 27.3 lbs (12.4%) at 72 weeks using the efficacy estimand. In a key secondary endpoint, 59.6% of participants taking the highest dose of orforglipron lost at least 10% of their body weight, while 39.6% lost at least 15% of their body weight. In addition to achieving significant weight loss, orforglipron was also associated with reductions in known markers of cardiovascular risk, including non-HDL cholesterol, triglycerides and systolic blood pressure in pooled analyses across all doses. In a pre-specified exploratory analysis, the highest dose of orforglipron reduced high-sensitivity C-reactive protein (hsCRP) levels by 47.7%. Efficacy Estimand ResultsOrforglipron 6 mg Orforglipron 12 mg Orforglipron 36 mg Placebo Primary Endpoint Mean percent change in body weight from of 103.2 kg(227.5 lbs) and 37.0 BMIi -7.8% (-8.0 kg; -17.6 lbs) -9.3% (-9.4 kg; -20.7 lbs) -12.4% (-12.4 kg; -27.3 lbs) -0.9% (-1.0 kg; -2.2 lbs) Key Secondary Endpoints Percentage of participants achievingbody weight reductionsof ≥10%i 35.9 % 45.1 % 59.6 % 8.6 % Percentage of participants achieving body weight reductionsof ≥15%i 16.5 % 24.0 % 39.6 % 3.6 % iSuperiority test was adjusted for multiplicity. For the treatment-regimen estimand,2 each dose of orforglipron led to statistically significant improvements across the primary and all key secondary endpoints. Percent weight reduction: -7.5% (-7.8 kg; 17.2 lbs; 6 mg), -8.4% (-8.6 kg; 19.0 lbs; 12 mg), -11.2% (-11.3 kg; 25.0 lbs; 36 mg), -2.1% (-2.4 kg; 5.3 lbs; placebo) Percentage of participants achieving body weight reductions of ≥10%: 33.3% (6 mg), 40.0% (12 mg), 54.6% (36 mg), 12.9% (placebo) Percentage of participants achieving body weight reductions of ≥15%: 15.1% (6 mg), 20.3% (12 mg), 36.0% (36 mg), 5.9% (placebo) The overall safety profile of orforglipron in ATTAIN-1 was consistent with the established GLP-1 receptor agonist class. The most commonly reported adverse events were gastrointestinal-related and generally mild-to-moderate in severity. The most common adverse events for participants treated with orforglipron (6 mg, 12 mg and 36 mg, respectively) were nausea (28.9%, 35.9% and 33.7%) vs. 10.4% with placebo, constipation (21.7%, 29.8% and 25.4%) vs. 9.3% with placebo, diarrhea (21.0%, 22.8% and 23.1%) vs. 9.6% with placebo, vomiting (13.0%, 21.4% and 24.0%) vs. 3.5% with placebo, and dyspepsia (13.0%, 16.2% and 14.1%) vs. 5.0% with placebo. Treatment discontinuation rates due to adverse events were 5.1% (6 mg), 7.7% (12 mg) and 10.3% (36 mg) for orforglipron vs. 2.6% with placebo. The overall treatment discontinuation rates were 21.9% (6 mg), 22.5% (12 mg) and 24.4% (36 mg) for orforglipron vs. 29.9% with placebo. No hepatic safety signal was observed. The detailed ATTAIN-1 results will be presented next month at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 and published in a peer-reviewed journal. More results from the ATTAIN Phase 3 clinical trial program will be shared later this year, along with findings from the ACHIEVE Phase 3 clinical trial program evaluating orforglipron for adults with type 2 diabetes. About orforglipron Orforglipron (or-for-GLIP-ron) is an investigational, once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.3 Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. Chugai and Lilly published the preclinical pharmacology data of this molecule together.4 Lilly is running Phase 3 studies on orforglipron for the treatment of type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related medical problem. It is also being studied as a potential treatment for obstructive sleep apnea (OSA) and hypertension in adults with obesity. About ATTAIN-1 and ATTAIN clinical trial program ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron 6 mg, 12 mg and 36 mg as monotherapy to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, OSA or cardiovascular disease, who did not have diabetes. The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan in 3:3:3:4 ratio to receive either 6 mg, 12 mg or 36 mg orforglipron or placebo. The primary objective of the study was to demonstrate that orforglipron (6 mg, 12 mg, 36 mg) is superior to placebo in body weight reduction from baseline after 72 weeks in people with a BMI ≥30.0 kg/m² or a BMI ≥27.0 kg/m² with at least one weight-related comorbidity and a history of at least one self-reported unsuccessful dietary effort to lose body weight. All participants in the orforglipron treatment arms started the study at a dose of orforglipron 1 mg once-daily and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 6 mg (via steps at 1 mg and 3 mg), 12 mg (via steps at 1 mg, 3 mg and 6 mg) or 36 mg (via steps at 1 mg, 3 mg, 6 mg, 12 mg and 24 mg). Dose reduction was only allowed for GI tolerability if other mitigations failed. The ATTAIN Phase 3 global clinical development program for orforglipron has enrolled more than 4,500 people with obesity or overweight across two global registration trials. The program began in 2023 with additional results anticipated this year. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram and LinkedIn. P-LLY Endnotes and References: The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) for 72 weeks without initiating prohibited weight management treatments. The treatment-regimen estimand represents the estimated average treatment effect regardless of adherence to study intervention or initiation of prohibited weight management treatments. Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832. doi: 10.1007/s13300-024-01554-1. Epub 2024 Feb 24. PMID: 38402332; PMCID: PMC10951152. T. Kawai, B. Sun, H. Yoshino, D. Feng, Y. Suzuki, M. Fukazawa, S. Nagao, D.B. Wainscott, A.D. Showalter, B.A. Droz, T.S. Kobilka, M.P. Coghlan, F.S. Willard, Y. Kawabe, B.K. Kobilka, & K.W. Sloop, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967, (2020). Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about orforglipron as a potential treatment for adults with obesity or overweight, Lilly's ability to supply orforglipron, if approved, and the timeline for future readouts, presentations, and other milestones relating to orforglipron and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that orforglipron will prove to be a safe and effective treatment for obesity or overweight, that orforglipron will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Refer to: Brooke Frost; 317-432-9145 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Sign in to access your portfolio
